New hope for tough blood cancers? early trial launches

NCT ID NCT07556822

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug called HRS-3005 in 190 adults with B-cell blood cancers (like lymphoma or leukemia) that have returned or not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it can shrink tumors. Because it is a Phase 1 trial, the focus is on safety, not yet on proving it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-3005
What this could lead to: If it works, this could point toward a new treatment option for people with certain blood cancers that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 190 participants, so it is too soon to know if HRS-3005 is safe or effective. Many early-stage drugs do not succeed in later trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B-CELL MALIGNANCY

Contacts and locations

Locations

Hematology Hospital of the Chinese Academy of Medical Sciences
RECRUITING

Tianjin, Tianjin Municipality, 300020, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.